Market closed
Eyenovia/EYEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eyenovia
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Ticker
EYEN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
57
Website
Eyenovia Metrics
BasicAdvanced
$45M
Market cap
-
P/E ratio
-$0.79
EPS
1.74
Beta
-
Dividend rate
Price and volume
Market cap
$45M
Beta
1.74
52-week high
$2.57
52-week low
$0.37
Average daily volume
879K
Financial strength
Current ratio
0.46
Quick ratio
0.153
Long term debt to equity
-232.763
Total debt to equity
-660.866
Interest coverage (TTM)
-13.25%
Management effectiveness
Return on assets (TTM)
-92.94%
Return on equity (TTM)
-914.66%
Valuation
Price to revenue (TTM)
776.577
Price to book
-12.18
Price to tangible book (TTM)
-3.4
Price to free cash flow (TTM)
-0.755
Growth
Earnings per share change (TTM)
14.17%
3-year revenue growth (CAGR)
-82.64%
3-year earnings per share growth (CAGR)
-0.09%
What the Analysts think about Eyenovia
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Eyenovia stock.
Eyenovia Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Eyenovia Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Eyenovia News
AllArticlesVideos
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
GlobeNewsWire·2 weeks ago
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
GlobeNewsWire·4 weeks ago
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Eyenovia stock?
Eyenovia (EYEN) has a market cap of $45M as of October 26, 2024.
What is the P/E ratio for Eyenovia stock?
The price to earnings (P/E) ratio for Eyenovia (EYEN) stock is 0 as of October 26, 2024.
Does Eyenovia stock pay dividends?
No, Eyenovia (EYEN) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Eyenovia dividend payment date?
Eyenovia (EYEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Eyenovia?
Eyenovia (EYEN) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.